ADL

Linus Health Presents New Data on AI-Based Cognitive Assessments at AAIC 2023

Retrieved on: 
Tuesday, July 18, 2023
Health, General Health, Digital clock, DCR, DSM-IV codes, Dementia, Saint Louis University Mental Status Exam, Deficit spending, PET, Research, Functional dependency, MCI, Doctor of Philosophy, Davos, Disability, ADL, AAIC, Triage, Amyloid, Nature, Recall test, Montreal Cognitive Assessment, Assessment, Indiana University School of Medicine, Patient, AD, Conference, Medicine, Medical imaging, MD, Neurology

Building on its award-winning DCTclock™ test, Linus Health introduced its next-generation digital cognitive assessment , the Digital Clock and Recall (DCR™) in 2021.

Key Points: 
  • Building on its award-winning DCTclock™ test, Linus Health introduced its next-generation digital cognitive assessment , the Digital Clock and Recall (DCR™) in 2021.
  • The DCR combines DCTclock with word recall tasks and is part of a growing set of assessments and questionnaires available on the company’s research platform .
  • These newest studies showcase the technology’s ability to deliver rich insights into brain health beyond cognitive function alone, with additional data related to a key Alzheimer’s disease (AD) biomarker (PET amyloid) and new data pertaining to functional impairment.
  • For a full view of all studies involving Linus Health at the event, click here .

Introducing the Anbio ADL i1910: An Elegant CLIA Analyzer for Comprehensive Clinical Testing

Retrieved on: 
Tuesday, July 11, 2023
Learning curve, Infection, Plasma, CLIA, Health, Laboratory, Serum, ADL, Medical device, Medical imaging, Nursing

FRANKFURT, Germany, July 11, 2023 /PRNewswire/ -- Anbio, a leading provider of innovative diagnostic solutions, proudly presents the Anbio ADL i1910, a fully automated, compact, and affordable CLIA analyzer designed to transform the landscape of clinical diagnostics.

Key Points: 
  • FRANKFURT, Germany, July 11, 2023 /PRNewswire/ -- Anbio, a leading provider of innovative diagnostic solutions, proudly presents the Anbio ADL i1910, a fully automated, compact, and affordable CLIA analyzer designed to transform the landscape of clinical diagnostics.
  • Key Features of the Anbio ADL i1910:
    Extensive Assay Menu: The ADL i1910 boasts an impressive range of 49 developed assays, allowing for both qualitative and quantitative testing of analytes.
  • "Anbio is proud to introduce the ADL i1910, a breakthrough CLIA analyzer that revolutionizes clinical diagnostics," said Jack Davis, Chief Business Officer at Anbio.
  • The Anbio ADL i1910 is set to transform the field of clinical diagnostics, empowering healthcare providers with a cost-effective and comprehensive solution.

University of Phoenix Hosts July Educational Equity Webinar

Retrieved on: 
Monday, July 10, 2023
Professional Services, Continuing, University, DEI (Diversity, Equity and Inclusion), Education, ACT, Southern Division, Beacham, Brainstorm, The Advisory Board Company, American University, Inclusive, EDI, Impact, Collegiate summer baseball, MBA, DEIB, Advisory board, ADL, OEE, University of Phoenix, Organization, Definition, School, Student, Alonzo A. Crim Open Campus High School, Faculty, Inclusion, Growth, Socialization, Educational equity, Lens, Management

University of Phoenix is holding the newest webinar in its Educational Equity Webinar Series, titled “Mirrors, Windows and Lenses: The Impact of Early Messages,” on July 20, 2023, at 11 AM AZT.

Key Points: 
  • University of Phoenix is holding the newest webinar in its Educational Equity Webinar Series, titled “Mirrors, Windows and Lenses: The Impact of Early Messages,” on July 20, 2023, at 11 AM AZT.
  • "We are thrilled to welcome back Erin Beacham and Perri Chandler to continue this rich discussion around stereotypes and assumptions," shares Tondra Richardson, MBA, Director of Student Diversity & Inclusion at the University of Phoenix.
  • The discussion will be hosted by Tondra Richardson, MBA, director of Student Diversity & Inclusion and Saray Lopez, MBA, director, Student Diversity & Inclusion, both with the Office of Educational Equity (OEE) at University of Phoenix.
  • The Educational Equity Webinar Series is part of a series of events with which the OEE engages aiming to foster cultural awareness, thought leadership and community alliances to promote and sustain educational equity and diversity initiatives.

Alteryx Fuels Finance Transformation with Decision Intelligence and Intelligent Automation Leveraging the Power of AWS

Retrieved on: 
Monday, July 10, 2023
Cloud, Amazon Web Services, Analytics, Alteryx, Financial system in Australia, Automation, ADL, Madhu, CFOS, AYX, Machine learning, Organization, Artificial intelligence, ISV, Environment, AWS, NYSE, Data science, Retail, Sales, Cryptocurrency, Online shopping

IRVINE, Calif., July 10, 2023 /PRNewswire/ -- Alteryx, Inc. (NYSE: AYX), the Analytics Cloud Platform company, today announced decision intelligence and intelligent automation capabilities on Amazon Web Services (AWS) designed to empower chief financial officers (CFOs) and finance leaders to embrace cloud and data analytics as strategic tools for their modernization goals.

Key Points: 
  • Changing regulations and manual processes in the office of finance often mean repetitive work, time consuming data input, and hours of labor spent in preparing spreadsheets.
  • The Alteryx intelligent automation capabilities available on AWS maximize the benefits of cloud for office of finance teams by modernizing processes that help them solve more complex data problems and adapt to constantly changing market environments.
  • Digitally upskill across finance: Alteryx provides a self-service, low-code/no-code environment so that an analyst or business user can quickly upskill in data and analytics while leveraging the power and scalability of AWS.
  • "With Alteryx Analytics Automation powered by AWS, finance teams can innovate and modernize tax and audit processes with automated self-service analytics that streamline and accelerate traditional compliance work," said Madhu Raman, worldwide head of automation at AWS.

BAE Systems Awarded Next Generation Launcher Design Contract

Retrieved on: 
Thursday, July 6, 2023
Defense, Technology, Aerospace, Manufacturing, Other Technology, Other Defense, Contracts, U.S. Navy type commands, Vertical, Multimedia, NSPO, ADL, ESSM, Mark 41 Vertical Launching System, Evolution, BAE Systems, DOTC, BAE, Credit, Arms industry

BAE Systems was awarded a $37 million U.S. Department of Defense Ordnance Technology Consortium (DOTC) contract to design the Next Generation Evolved SeaSparrow Missile Launch System (NGELS).

Key Points: 
  • BAE Systems was awarded a $37 million U.S. Department of Defense Ordnance Technology Consortium (DOTC) contract to design the Next Generation Evolved SeaSparrow Missile Launch System (NGELS).
  • View the full release here: https://www.businesswire.com/news/home/20230706685829/en/
    The Next Generation Evolved SeaSparrow Missile Launch System (NGELS) is a deck-mounted, fixed-angle launcher that leverages BAE Systems’ Adaptable Deck Launcher (ADL) concept to store and launch ESSMs from Mk 25 missile canisters.
  • (Credit: BAE Systems)
    NGELS is a deck-mounted, fixed-angle launcher that leverages BAE Systems’ Adaptable Deck Launcher (ADL) concept to store and launch ESSMs from Mk 25 missile canisters, which are also produced by BAE Systems.
  • “We have a long history of providing missile integration, launching systems, and canister design to the U.S. Navy,” said Brent Butcher, vice president of the weapon systems product line at BAE Systems.

Glatfelter’s GlatPure™ ADL and Absorbent Core Earns OK Biobased Certification from TUV Austria

Retrieved on: 
Thursday, June 15, 2023
Certification, NYSE, Austria, OK, ADL, USDA, Carbon, GLT, Tissue paper

CHARLOTTE, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Glatfelter Corporation (NYSE: GLT), a leading global supplier of engineered materials, is pleased to announce that its GlatPure™ Acquisition Distribution Layers (ADL) and Absorbent Core have received the prestigious class 4 OK Biobased certification from TUV Austria, with the biobased carbon content of GlatPure™ ADL and Absorbent Core being at 100%.

Key Points: 
  • CHARLOTTE, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Glatfelter Corporation (NYSE: GLT), a leading global supplier of engineered materials, is pleased to announce that its GlatPure™ Acquisition Distribution Layers (ADL) and Absorbent Core have received the prestigious class 4 OK Biobased certification from TUV Austria, with the biobased carbon content of GlatPure™ ADL and Absorbent Core being at 100%.
  • This certification reinforces Glatfelter’s dedication to environmental sustainability and eco-friendly practices within the absorbent hygiene industry.
  • The OK Biobased certification from TUV Austria is a recognized global standard for verifying the biobased content of products.
  • “We are thrilled to receive this certification for our GlatPure™ ADL and Absorbent Core,” said Vishal Bansal, Vice President, Global Innovation & Product Sustainability.

Cala® Launches The Cala kIQ™ System, Offering Meaningful Tremor Relief for Patients With Essential Tremor and Now Parkinson’s Disease

Retrieved on: 
Wednesday, June 14, 2023
Biotechnology, General Health, Medical Devices, Health, Health Technology, Medicine, Minneapolis Veterans Affairs Health Care System, Posture, Tremor, Physiology, Research, Movement, Essential tremor, ADL, Parkinson's disease, Patient, Physician, Veterans' affairs, FDA, FAAN, Conditional sentence, Advantage, Pharmaceutical industry, Medical device

“At Cala, we’ve always been committed to expanding patient access and accelerating innovation in TAPS therapy for indications beyond essential tremor,” said Renee Ryan, CEO at Cala.

Key Points: 
  • “At Cala, we’ve always been committed to expanding patient access and accelerating innovation in TAPS therapy for indications beyond essential tremor,” said Renee Ryan, CEO at Cala.
  • Millions of people across the US live with essential tremor or Parkinson’s disease, and diagnoses continue to rise.
  • The Cala kIQ System measures each patient's unique tremor physiology and individualizes a stimulation pattern for tremor relief.
  • Cala is working to secure additional coverage and reimbursement for the new breakthrough designated Parkinson's disease indication for the Cala kIQ System.

Active Pharmaceutical Ingredients and High Potency API Industry Banks on API Portfolio - Grand View Research, Inc.

Retrieved on: 
Tuesday, June 6, 2023
Wuxi, Laboratory, Drug development, Production Linked Incentive schemes in India, Teva Active Pharmaceutical Ingredients, API, Lonza, CMOS, PDL, Cancer, Medicine, USD, ADL, Projection, Acquisition, Traction, Novartis, Investment, Quality control, SAN, Growth, Novasep, Mortality, American Cancer Society, FDA, Red Data Book of Ukraine, PLI, Fine chemical

SAN FRANCISCO, June 6, 2023 /PRNewswire/ -- The global active pharmaceutical ingredients and high potency API industry size stood at USD 233.31 billion in 2021 and is poised to observe a CAGR of 6% from 2022 to 2030, according to the " Active Pharmaceutical Ingredients and High Potency API Industry Data Book, 2023 – 2030 ," published by Grand View Research.

Key Points: 
  • SAN FRANCISCO, June 6, 2023 /PRNewswire/ -- The global active pharmaceutical ingredients and high potency API industry size stood at USD 233.31 billion in 2021 and is poised to observe a CAGR of 6% from 2022 to 2030, according to the " Active Pharmaceutical Ingredients and High Potency API Industry Data Book, 2023 – 2030 ," published by Grand View Research.
  • Besides, the adoption of a sedentary lifestyle and soaring cancer cases have propelled the development of API.
  • The global API market size was valued at USD 209.71 billion in 2021 and will exhibit a 5.9% CAGR between 2022 and 2030.
  • Order your copy of the Free Sample of "Active Pharmaceutical Ingredients and High Potency API Industry Data Book - Active Pharmaceutical Ingredients and High Potency Active Pharmaceutical Ingredients Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030" Data Book, published by Grand View Research
    Industry leaders are counting on the high efficiency of HPAPI molecules to solidify their position in the global landscape.

Active Pharmaceutical Ingredients and High Potency API Industry Banks on API Portfolio - Grand View Research, Inc.

Retrieved on: 
Tuesday, June 6, 2023
Wuxi, Laboratory, Drug development, Production Linked Incentive schemes in India, Teva Active Pharmaceutical Ingredients, API, Lonza, CMOS, PDL, Cancer, Medicine, USD, ADL, Projection, Acquisition, Traction, Novartis, Investment, Quality control, SAN, Growth, Novasep, Mortality, American Cancer Society, FDA, Red Data Book of Ukraine, PLI, Fine chemical

SAN FRANCISCO, June 6, 2023 /PRNewswire/ -- The global active pharmaceutical ingredients and high potency API industry size stood at USD 233.31 billion in 2021 and is poised to observe a CAGR of 6% from 2022 to 2030, according to the " Active Pharmaceutical Ingredients and High Potency API Industry Data Book, 2023 – 2030 ," published by Grand View Research.

Key Points: 
  • SAN FRANCISCO, June 6, 2023 /PRNewswire/ -- The global active pharmaceutical ingredients and high potency API industry size stood at USD 233.31 billion in 2021 and is poised to observe a CAGR of 6% from 2022 to 2030, according to the " Active Pharmaceutical Ingredients and High Potency API Industry Data Book, 2023 – 2030 ," published by Grand View Research.
  • Besides, the adoption of a sedentary lifestyle and soaring cancer cases have propelled the development of API.
  • The global API market size was valued at USD 209.71 billion in 2021 and will exhibit a 5.9% CAGR between 2022 and 2030.
  • Order your copy of the Free Sample of "Active Pharmaceutical Ingredients and High Potency API Industry Data Book - Active Pharmaceutical Ingredients and High Potency Active Pharmaceutical Ingredients Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030" Data Book, published by Grand View Research
    Industry leaders are counting on the high efficiency of HPAPI molecules to solidify their position in the global landscape.

Arthur D. Little: Companies Miss Out on Boosting Their Innovation Return on Investment by, on Average, 30%

Retrieved on: 
Monday, June 5, 2023
Professional Services, Business, Technology, Other Technology, Finance, Research, Science, Benchmark, Arthur, COVID-19, Organization, Ecosystem, Arthur D. Little, Agile, Investment, KPI-driven code analysis, ADL, Renewable energy, Fine chemical, Management

Companies report a 33 percent drop in satisfaction with their innovation performance over the same period.

Key Points: 
  • Companies report a 33 percent drop in satisfaction with their innovation performance over the same period.
  • “Companies with strong innovation management practices are able to identify properly their specific limiting factors, eliminate them, and gain significant return for R&D spend.
  • “Increasing R&D spending is a bad idea and will reduce return on innovation – unless your innovation management practices are already in the top quartile of our cross-industry benchmark.
  • The result is new and calibrated insight into the key areas that can often dramatically increase their innovation performance.